RYBREVANT® plus lazertinib outperforms osimertinib in prolonging progression-free survival for high-risk EGFR-mutated NSCLC patients.
In a recent study, the combination of RYBREVANT® (Amivantamab-Vmjw) and lazertinib showed longer progression-free survival compared to osimertinib for patients with EGFR-mutated non-small cell lung cancer (NSCLC) at high risk. This chemotherapy-free regimen has the potential to address a significant unmet need for such patients, who typically face high-risk disease.
May 31, 2024
5 Articles